BIO 2009 Coverage
This year's BIO show, May 19-22 in Atlanta, drew 14,352 attendees.
This page will provide news, blogs, articles, video and audio coverage from BIO 2009. Check back for updates.
Table of Contents
Videos
BIO 2009: Sir Elton John's Keynote Address
Musician and AIDS activist Sir Elton John delivers the keynote address at this year's BIO show in Atlanta.
Sanofi Opens Up, Looking for a Few Good Partners
Sanofi-Aventis is undergoing a major internal shift, opening itself up more and more to external partnerships and “access to innovation.” Senior VP Jean-Claude Muller talks about making alliances work, and how Sanofi’s new bio plant outside Paris figures in the mix.
Symyx QbD Strategy
Symyx Technology's Eric Carlson and Matthew Pino discuss how Symyx's new CDMO capability conforms with the industry's Quality by Design and automation needs.
Progressive Peptides: Unigene Pushes New Methods, New Deliveries
Unigene Labs’ proprietary technology accelerates peptide yield and purity by secreting the product of interest into a media; the company is also paving the way to oral and nasal delivery of peptide therapies, explains VP of Product Development Jim Gilligan.
Bio in Brazil: Positioned for Growth
Biominas Foundation CEO, Eduardo Soares discusses how Brazil is prepping for growth in BIO and looking for guidance from other regulatory agencies.
A CMO’s Work is Never Done, Even in Academia
Out of necessity, CMO’s today must be incredibly nimble, flexible, and aggressive. Nebraska-Lincoln’s Mike Meagher shares secrets of navigating a market in which the future is always uncertain, and every client demands immediate attention.
Expanded Bed Chromatography: “Rhobust”, Flexible
Expanded bed chromatography, not new to pharma, can process unclarified feedstocks simply and flexibly, with disposable tubing that eliminates the need for CIP. Rob Noel of Upfront Chromatography A/S shares the ins and outs of his company’s Rhobust system.
Women In Bio: Get Connected
Sr. Digital Editor, Michele V. Wagner discusses the opportunities for women in the life sciences with Women In Bio's President Elect, Lynn Johnson Langer, and President Emeritus, Robbie Melton.
Wyeth BioPharma: Pfizerized or Not?
Wyeth SVP Michael Kowolenko rebuts the idea that Pfizer will be detrimental to Wyeth BioPharma and its continuous improvement culture.
Back to TopArticles & News
Bioscience Education Study Finds Some States Lagging
First-ever report by Battelle, BIO and Biotechnology Institute finds wide disparities in achievement and uneven program efforts
Bio QbD at Pfizer, Genentech: Shifting from Concept to Implementation
Think QbD is daunting? Double that for the biotech arena.
Scoring Biotech Innovation (and Keeping Your Career Options Open)
The U.S. may still lead, but it can’t rule in every aspect of the industry, says author and blogger Yali Friedman, who also touched on career and workforce issues at BIO 2009
Biosimilars, QbD Reshape the Biopharma Landscape: An Interview with Patricia Seymour
The senior BioProcess Consultant took a few minutes to share her views on the forces driving biotech forward at BIO 2009
Genentech: Addressing the Worldwide Inspection Burden
Increasingly common facility visits are costly, disruptive and, for the most part, unnecessary, says Genentech’s O’Connor.
Regulatory Babel: Another Case for Harmonization
Novo Nordisk’s Birgitte Holst makes the case for getting global regulators on the same page more often.
Retooling Biotech Education: an Interview with Battelle’s Mitch Horowitz
At BIO 2009, Battelle Managing Partner Mitch Horowitz unveiled the first Biotechnology Education Report card, a collaboration between BIO, Battelle and the Biotech Institute, which ranked each of the 50 states on the strength of its biotech training efforts. We spoke with Mr. Horowitz briefly at BIO. Keys to improving biotech education, he says, will be establishing national standards, improving teacher training and re-evaluating pay, and, above all, awakening a sense of excitement in young people about science.
Back to TopPodcasts
A World Beyond ICH: WHO, ISO Must Figure Prominently in Harmonization
Regulatory harmonization has made great strides, but if efforts are to become truly global the World Health Organization must be involved. In this audio interview, Birgitte Holst, Manager of Manufacturing Science & Quality at Novo Nordisk, discusses pharmacopeia, terminology, anticounterfeiting, and more.
Puerto Rico 2.0: Repositioning an Industry to Restore a Competitive Edge
No one needs to tell Puerto Rico the global pharmaceutical market has changed. The island is in the midst of a makeover that will focus on biotech, generics, and outsourcing its 40-plus years of expertise with the aim of keeping the island relevant to pharma. INDUNIV executive director Ivan Lugo talks strategy.
It’s Good to Be a Scientist: Life Sciences Job Market Holding Firm
The turmoil in life sciences and merging of small- and large-molecule manufacturers only enhances the attractiveness of experienced scientists and engineers, says Kurt Moore, president of TalentWRx staffing agency. For those whose careers are in flux, making the most of a temporary position may open doors to something more permanent.
Are QbD, Lean, and Time to Market Competing Concepts?
In today’s pharma world, speed to market often trumps QbD, while QbD can crowd out Lean and other operational excellence initiatives. It doesn’t have to be so, says Tunnell Consulting’s Bryan Winship, who also explains how to avoid the middle-management “black hole” in QbD efforts.
Locating the Magic Spot in Mammalian Cell Lines
Catalent Pharmaceuticals’ new GPEx technology is a gene expression method which inserts genes into target cells, eliminating the need for markers. Mike Jenkins, GM of Catalent’s Middleton, Wis., facility explains how GPEx helps manufacturers turn the corner, quickly, from research to development.
Pulmonary Aerodynamics: Creating Nanostructures Out of Drugs (not Polymers)
Savara, Inc. out of Austin, Texas, specializes in reformulating successful drugs for use in standard inhalable devices, by engineering the nano “whiffle ball” out of the drug itself, or a combination of drugs. Executive chairman Rob Neville explains in this audio.
Back to TopBlog Commentary
Notes from BIO 2009: On Genentech's Bio-QbD Pilot and Impending "A-MAb" Case Study
Notes from BIO 2009: Up to $400,000/Day to Support an Inspection, Genentech Says
Notes from BIO 2009: Limited Swag but Plenty of Hand Sanitizer
Notes from BIO 2009: Irish Pharma--Can Innovation and Quality Trump Cost and Infrastructure Considerations?
Notes from BIO 2009: Basketball Star Dominique Wilkins Roams Show Floor
Back to TopProducts & Services
Vetter: Prefilled Syringe Provides a High-Quality Solution for Drug Reconstitution
DSM Pharmaceuticals: Manufacturing Services Provide a Turn-Key Biologic Manufacturing Solution that Reduces Cost and Risk
Aptuit: Facility for Developing and Manufacturing Anticancer Drugs and Other High-Potency Compounds
Symyx Technologies: Organization Helps Biopharmaceutical Companies Move Promising Drug Candidates to Clinical Trials Faster
Back to Top